Perflutren - Molecular Biosystems

Drug Profile

Perflutren - Molecular Biosystems

Alternative Names: FS-069; Octafluoropropane; Optison; Perfluoropropane

Latest Information Update: 10 Aug 2010

Price : $50

At a glance

  • Originator Molecular Biosystems
  • Developer Chugai Pharmaceutical; GE Healthcare; Molecular Biosystems; OncoGenex Pharmaceuticals
  • Class Contrast media; Fluorocarbons
  • Mechanism of Action Ultrasonography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Left ventricular dysfunction

Most Recent Events

  • 25 Jun 2009 CHMP of the EMEA recommends the lifting of the suspension of the marketing authorisation for Perflutren in the European Union
  • 21 Aug 2008 OncoGenex Technologies has merged with Sonus Pharmaceuticals to form OncoGenex Pharmaceuticals
  • 22 Apr 2005 Discontinued - Phase-II/III for Left ventricular dysfunction (diagnosis) in Japan (Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top